一种新型的PROTAC G9a/GLP降解剂,类似于G9a siRNA,可以抑制MCF-7乳腺癌细胞的迁移而不会影响其增殖
Anirban Mukherjee1, Yasunobu Yamashita1, Ryo Maeda2
1SANKEN, The University of Osaka, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, JAPAN.
Journal of medicinal chemistry
|August 31, 2025
概括
一种新型的G9a/GLP降解剂,化合物4,有效地减少癌症驱动蛋白质而无毒性. 这种化合物抑制乳腺癌细胞迁移,为G9a/GLP研究和药物发现提供了有前途的工具.
科学领域:
- 生物化学
- 表观遗传学
- 癌症生物学
背景情况:
- G9a和G9a类蛋白 (GLP) 是对表观遗传调节至关重要的基因组甲基转移酶.
- G9a/GLP的失调与癌症的扩散,进展和转移有关.
- 现有的基纳基G9a/GLP抑制剂在正常细胞中表现出毒性.
研究的目的:
- 为生物研究确定一种毒性较低的G9a/GLP降解剂.
- 评估一种新型G9a/GLP降解剂 (化合物4) 在乳腺癌细胞中的疗效.
- 探索第4种化合物的潜力,
主要方法:
- 开发一种基于RK-701抑制剂的新型G9a/GLP降解剂 (化合物4).
- 用化合物4治疗乳腺癌MCF-7细胞
- 评估G9a/GLP蛋白含量,组织蛋白甲基化,细胞活力和细胞迁移.
- 将化合物4与G9a小干扰RNA (siRNA) 的作用进行比较.
主要成果:
- 化合物4有效降低了MCF-7细胞中的G9a/ GLP蛋白和甲基化组素水平.
- 与一些基纳胺抑制剂不同,化合物4并没有抑制细胞活力.
- 通过化合物4降解G9a/GLP抑制了MCF-7细胞迁移,类似于G9a siRNA.
结论:
- 化合物4是研究G9a/GLP生物学的有价值,毒性较低的工具.
- 化合物4显示为开发针对G9a/GLP的新型癌症疗法的主要化合物.
- 这些发现支持进一步研究G9a/GLP降解作为癌症治疗策略.
更多相关视频
相关概念视频
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...